Getinge has announced a new social bond issuance of SEK 570 million aimed at enhancing the production capacity of life-saving medical technologies. The new bond, issued on June 3, 2021, was oversubscribed shortly after launch, reflecting strong investor interest. Funds will specifically support the manufacturing of extracorporeal life support (ECLS) products and BetaBags®, essential for drug production safety amid increasing demand due to the COVID-19 pandemic. This initiative underscores Getinge's commitment to sustainability and social benefits.
Summary not available.
Getinge's Neurally Adjusted Ventilatory Assist (NAVA) technology demonstrated significant clinical effectiveness in the NAVIATOR trial, reducing mechanical ventilation time for adult patients with acute respiratory failure by nearly 35%. Conducted across 14 centers, the trial involved 306 patients and highlighted improvements in health economics by potentially freeing up ICU resources. The study supports NAVA's routine use in intensive care settings. This advancement indicates continued growth potential for Getinge's innovative ventilation solutions in the market.
Getinge has made significant advancements in neonatal and adult ventilation technologies, particularly with the Neurally Adjusted Ventilatory Assist (NAVA) technique, which improves patient outcomes. A recent study indicates that NAVA reduces the time patients spend on ventilators and lowers extubation failure rates. Sabina Checketts, a neonatal doctor who survived premature birth, actively utilizes NAVA to enhance breathing for at-risk infants and supports its application in adult care.